TY - JOUR
T1 - Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer’s disease
AU - Kobayashi, Nobuyuki
AU - Shinagawa, Shunichiro
AU - Niimura, Hidehito
AU - Kida, Hisashi
AU - Nagata, Tomoyuki
AU - Tagai, Kenji
AU - Shimada, Kazuya
AU - Oka, Naomi
AU - Shikimoto, Ryo
AU - Noda, Yoshihiro
AU - Nakajima, Shinichiro
AU - Mimura, Masaru
AU - Shigeta, Masahiro
AU - Kondo, Kazuhiro
N1 - Funding Information:
The present work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (grant number 17K10318, 17K10317), the Japan Agency for Medical Research and Development (AMED) (Grant No. 18dk0207025h0003), Mitsui Life Social Welfare Foundation and Private University Research Branding Project from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). The funders were not involved in the design of the study or conducting it; in the collection, management, analysis, and interpretation of the data; or in the preparation, review and approval of the manuscript. Also, we would like to thank Mr. Alexander Cox for editorial assistance with the manuscript.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Early diagnosis of dementia including Alzheimer’s disease (AD) is an urgent medical and welfare issue. However, to date, no simple biometrics have been available. We reported that blood DNA methylation levels of the COASY gene, which encodes coenzyme A synthase, were increased in individuals with AD and amnestic mild cognitive impairment (aMCI). The present study sought to replicate these findings with larger numbers of samples. Another objective was to clarify whether COASY methylation is associated with neurodegeneration through a comparison of AD, AD with cardiovascular disease (CVD), and vascular dementia (VaD). We measured blood COASY methylation levels in normal controls (NCs) (n = 200), and individuals with aMCI (n = 22), AD (n = 151), and VaD (n = 21). Compared with NCs, they were significantly higher in individuals with aMCI and AD. Further, they were significantly higher in AD patients without cardiovascular diseases compared to AD patients with them. These findings suggest that COASY methylation levels may be related to neurodegeneration in AD.
AB - Early diagnosis of dementia including Alzheimer’s disease (AD) is an urgent medical and welfare issue. However, to date, no simple biometrics have been available. We reported that blood DNA methylation levels of the COASY gene, which encodes coenzyme A synthase, were increased in individuals with AD and amnestic mild cognitive impairment (aMCI). The present study sought to replicate these findings with larger numbers of samples. Another objective was to clarify whether COASY methylation is associated with neurodegeneration through a comparison of AD, AD with cardiovascular disease (CVD), and vascular dementia (VaD). We measured blood COASY methylation levels in normal controls (NCs) (n = 200), and individuals with aMCI (n = 22), AD (n = 151), and VaD (n = 21). Compared with NCs, they were significantly higher in individuals with aMCI and AD. Further, they were significantly higher in AD patients without cardiovascular diseases compared to AD patients with them. These findings suggest that COASY methylation levels may be related to neurodegeneration in AD.
UR - http://www.scopus.com/inward/record.url?scp=85088392791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088392791&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-69248-9
DO - 10.1038/s41598-020-69248-9
M3 - Article
C2 - 32699290
AN - SCOPUS:85088392791
SN - 2045-2322
VL - 10
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 12217
ER -
